The number of shares to be offered and the price range for the offering have not yet been determined. Lucid Diagnostics, a majority-owned subsidiary of New York-based medical technology company PAVmed Inc. (Nasdaq: PAVM), said in a news release that it intends to list its common stock on the Nasdaq Stock Market under the ticker symbol “LUCD.” (You can go here to read the IPO filing with the U.S. Securities and Exchange Commission.) Joint bookrunning managers for the offering are Cantor Fitzgerald and Canaccord Genuity, and BTIG and Needham are the co-lead managers.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published September 24, 2021.